SB2 investigational biosimilar candidate to Remicade ? ( infliximab ) : On November 9 , 2015 at the Annual Meeting of the American College of Rheumatology ( ACR ) and the Association for Rheumatology Health Professionals ( ARHP ) in San Francisco , Samsung Bioepis announced 54 week SB2 clinical study results that showed comparable safety and equivalent efficacy to Remicade ? , as evidenced in ACR20 response rate of 65 . 3 in the SB2 arm versus 69 . 2 in the Remicade ? arm . The SB2 study randomized 584 patients with moderate to severe rheumatoid arthritis despite methotrexate therapy across 73 sites in 11 countries . In March 2015 , Samsung Bioepis submitted to the EMA a Marketing Authorization Application for SB2 , for which a CHMP opinion has yet to be announced .
